We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

191 hedge funds and large institutions have $1.06B invested in BioCryst Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 57 increasing their positions, 71 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more call options, than puts

Call options by funds: $37.2M | Put options by funds: $23.2M

48% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 31

18% more capital invested

Capital invested by funds: $898M → $1.06B (+$165M)

8% more funds holding

Funds holding: 177 → 191 (+14)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

9.22% less ownership

Funds ownership: 68.29% → 59.07% (-9.2%)

20% less repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 71

Holders
191
Holders Change
+14
Holders Change %
+7.91%
% of All Funds
3.35%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
46
Increased
57
Reduced
71
Closed
31
Calls
$37.2M
Puts
$23.2M
Net Calls
+$13.9M
Net Calls Change
+$15.9M

Top Buyers

Rank Fund Capital Flow
1
HM
HealthCor Management
New York
+$50.4M
2
Artisan Partners
Artisan Partners
Wisconsin
+$31.2M
3
Goldman Sachs
Goldman Sachs
New York
+$19.3M
4
Invesco
Invesco
Georgia
+$14.4M
5
N
Nuveen
North Carolina
+$9.61M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$58.7M
2
State Street
State Street
Massachusetts
-$38.6M
3
DM
Deerfield Management
New York
-$33.3M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$24.1M
5
MWNA
Marshall Wace North America
New York
-$19.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
IFAM
176
Institutional & Family Asset Management
Colorado
$4K – – –
BCPWM
177
Bradley & Co Private Wealth Management
Florida
$4K +$3.81K +370 New
WAP
178
Wealthcare Advisory Partners
Pennsylvania
$4K +$4.12K +400 New
Daiwa Securities Group
179
Daiwa Securities Group
Japan
$3K – – –
GAM
180
Gemmer Asset Management
California
$2K -$2.06K -200 -50%
TWA
181
TCI Wealth Advisors
Arizona
$2K +$2.04K +198 New
CFA
182
Carroll Financial Associates
North Carolina
$2K +$3.03K +294 New
AIG
183
American International Group
New York
$1.05K +$2.81K +272 +0.3%
IHWM
184
Iron Horse Wealth Management
Iowa
$1K +$516 +50 New
PNC Financial Services Group
185
PNC Financial Services Group
Pennsylvania
$1K +$918 +89 New
NFG
186
Next Financial Group
Texas
$1K +$1.03K +100 New
Nisa Investment Advisors
187
Nisa Investment Advisors
Missouri
$121 +$92.8K +9,000 +308%
FGAM
188
Financial Gravity Asset Management
Texas
$55 +$52 +5 New
Point72 Asset Management
189
Point72 Asset Management
Connecticut
– -$24.1M -3,230,800 Closed
Voloridge Investment Management
190
Voloridge Investment Management
Florida
– -$7.74M -1,038,874 Closed
EP
191
Eversept Partners
New York
– -$3.66M -491,852 Closed
FAM
192
Formidable Asset Management
Ohio
– -$3.47M -470,419 Closed
PVI
193
Pura Vida Investments
New York
– -$3.07M -412,419 Closed
Millennium Management
194
Millennium Management
New York
– -$2.96M -286,632 Closed
QIM
195
Quantitative Investment Management
Virginia
– -$1.91M -256,210 Closed
ACM
196
Altium Capital Management
New York
– -$1.86M -250,000 Closed
Simplex Trading
197
Simplex Trading
Illinois
– -$2.17M -210,641 -84%
WP
198
Woodline Partners
California
– -$1.16M -155,844 Closed
SCM
199
Silverarc Capital Management
Massachusetts
– -$820K -110,000 Closed
OQS
200
Occudo Quantitative Strategies
Florida
– -$648K -87,019 Closed
5 6 7
8
9

BCRX Hedge Fund Activity: Q1 2021 in Review

191 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2021, worth a combined $1.06B — up 18% from $898M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new BCRX positions and 31 closed out — a net gain of 15 holders — while 57 added to existing stakes and 71 trimmed.

The largest buyer was HealthCor Management, opening a new position worth an estimated $50.4M. The largest seller was Citadel Advisors, cutting an estimated $58.7M.

  • 191 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2021, up from 177 in Q4 2020.
  • Funds reported $1.06B of BioCryst Pharmaceuticals stock for Q1 2021, up 18% quarter-over-quarter.
  • 46 funds opened new BioCryst Pharmaceuticals positions in Q1 2021 and 31 closed out, a net change of +15 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q1 2021 was HealthCor Management, an estimated $50.4M added.
  • The largest BioCryst Pharmaceuticals seller in Q1 2021 was Citadel Advisors, an estimated $58.7M sold.

Based on aggregated 13F filings for Q1 2021.